← 프로그램 목록
ADCApprovedRecruiting

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Daiichi SankyoAstraZeneca·Enhertu™

비교

Trastuzumab deruxtecan (T-DXd) with pyrotinib(Daiichi Sankyo / AstraZeneca)은 Breast Cancer 표적 ADC로, Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting hormone receptor. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 65.8% (ClinicalTrials.gov NCT04494425). 차별점: novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 9일 (5일 전)PK/독성 2026년 7월 9일 (5일 전)

Breast Cancer

Breast Cancer

Recruiting

Technology

구조모아 · Exatecan/DXd (TOP1)

ADC) is a next-generation antibody therapeutics designed to del

deruxtecan (Dato-DXd, Datroway ® )]

cleavable peptide linker and a topoisomerase I payload with byst

humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side

novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload

Mechanism of Action

targeting hormone receptor

topoisomerase I inhibitor exatecan, as its payload

TROP2 on cancer cell surface and, follow

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 78건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · N/A · Phase 2
  • Status: Recruiting · Not yet recruiting · Active, not recruiting
  • 주요 endpoint: Real World Time to Next Treatment (rwTTNT1) in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer · Type of Treatment Patterns in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer · Number of Physician-reported Safety Events of Interest in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer (T-DXd only) · Number of Participants Receiving Prophylactic and Reactive Treatment Management for Physician-reported Safety Events of Interest in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer (T-DXd only) · Real World Time to Permanent Treatment Discontinuation (rwTTD1) in Participants With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer
  • 등록된 결과: ORR 65.8%
  • 핵심: This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's ch…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Trastuzumab deruxtecan (T-DXd) with pyrotinib은 어떤 치료제인가요?
Trastuzumab deruxtecan (T-DXd) with pyrotinib(Daiichi Sankyo / AstraZeneca)은 Breast Cancer 표적 ADC로, Breast Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Trastuzumab deruxtecan (T-DXd) with pyrotinib의 임상 단계는?
Trastuzumab deruxtecan (T-DXd) with pyrotinib의 현재 단계는 Approved입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.